Novel treatment from a botanical formulation Si-Miao-Yong-an decoction inhibits vasa vasorum angiogenesis and stabilizes atherosclerosis plaques via the Wnt1/β-catenin signalling pathway
Open Access
- 31 August 2023
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 61 (1) , 1364-1373
Abstract
Si-Miao-Yong-An (SMYA) has been widely used for the clinical treatment of atherosclerosis (AS). Yet, its complete mechanism of action is not fully understood. To investigate the mechanism by which SMYA stabilizes AS plaques from the perspective of inhibiting vasa vasorum (VV) angiogenesis. We used male ApoE-/- mice to establish an AS model. The mice were divided into model, SMYA (11.7 mg/kg/d), and simvastatin (SVTT) (2.6 mg/kg/d) groups. Mice were given SMYA or SVTT by daily gavage for 8 weeks. HE staining, immunofluorescence double-labelling staining, and immunohistochemical staining were used to observe the pathological changes in the plaques. Finally, the protein and mRNA expression levels of the Wnt1/β-catenin signalling pathway were detected by Western blot and qRT-PCR, respectively. SMYA significantly attenuated cholesterol crystallization, and lipid accumulation in AS plaques, resulting in smaller plaque size (0.25 mm2 vs. 0.46 mm2), and lowering ratio of plaque to lumen area (20.04% vs. 38.33%) and VV density (50.64/mm2 vs. 98.02/mm2). Meanwhile, SMYA suppressed both the positive area percentage of Wnt1 (2.53 vs. 3.56), β-catenin (3.33 vs. 5.65) and Cyclin D1 (2.10 vs. 3.27) proteins in the aortic root plaques, and mRNA expression of Wnt1 (1.38 vs. 2.09), β-catenin (2.05 vs. 3.25) and Cyclin D1 (1.39 vs. 2.57). SMYA has a protective effect against AS, which may be related to its anti-VV angiogenesis in plaques, suggesting that SMYA has the potential as a novel botanical formulation in the treatment of AS.Keywords
Funding Information
- National Natural Science Foundation of China (81774232)
This publication has 42 references indexed in Scilit:
- Ki67 is a promising molecular target in the diagnosis of cancer (Review)Molecular Medicine Reports, 2014
- Synthesis, characterization, and evaluation of a novel inhibitor of WNT/β-catenin signaling pathwayMolecular Cancer, 2013
- Increased Expression of Visfatin in Monocytes and Macrophages in Male Acute Myocardial Infarction PatientsMediators of Inflammation, 2012
- Fibroblast Growth Factor-2 Is Required for Vasa Vasorum Plexus Stability in Hypercholesterolemic MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit modelJournal of Ethnopharmacology, 2012
- CD34 marks angiogenic tip cells in human vascular endothelial cell culturesAngiogenesis, 2012
- The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbitMolecular Biology Reports, 2010
- Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlationsClinical and Experimental Medicine, 2010
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancerBritish Journal of Cancer, 2009